Background
==========

A new lung adenocarcinoma classification system has been proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) \[[@B1]\]. In this classification, the micropapillary component (MPC) was recommended as a new subtype of lung adenocarcinoma in addition to the lepidic, acinar, papillary, and solid subtypes defined in the 2004 World Health Organization (WHO) classification \[[@B2]\]. MPC was defined as tumor cells growing in papillary tufts lacking fibrovascular cores and may float within alveolar spaces. MPC-predominant lung adenocarcinoma shows a high incidence of nodal metastasis and a poor prognosis \[[@B3]-[@B8]\]. MPC-predominant carcinomas developing in various other organs, such as the breast and urinary bladder, known as invasive micropapillary carcinoma, also have a poor prognosis. However, localization of MPC in the lungs is significantly different from that in the other organs; MPC in lung adenocarcinoma is distinguished by floating tumor cells within alveolar spaces (aerogenous micropapillary component, AMPC), while MPC in other organs has been observed primarily in the stroma as invasive components (stromal invasive micropapillary component, SMPC) \[[@B3],[@B4]\].

Few studies have examined lung adenocarcinoma with SMPC \[[@B9],[@B10]\]. Recently, we reported 2 cases of SMPC-predominant lung adenocarcinoma \[[@B9]\]. The proportion of SMPC in both tumors was greater than 50% in area. We observed that SMPC had a strong association with vascular invasion, similar to the cases of SMPC-predominant carcinoma in other organs. However, a large-scale investigation on pulmonary SMPC has not been conducted.

The aims of this study included: (1) clarifying the incidence of SMPC in lung adenocarcinoma; (2) elucidating the clinicopathological characteristics of the tumor; and (3) determining the prognoses of the SMPC-positive (SMPC(+)) tumors and comparing them with those of SMPC-negative (SMPC(-)) tumors. We reviewed 559 resected lung adenocarcinomas for this study with performing immunohistochemical and genetic analysis.

Methods
=======

Patients
--------

We analyzed 565 consecutive cases of primary lung adenocarcinoma treated by surgical resection at the Kanagawa Cancer Center between February 2007 and December 2010. Formalin fixation of the resected lung tissue was performed within 48 hours to reduce the loss of immunohistochemical antigen expression and degeneration of DNA. Six patients who had received preoperative chemotherapy were excluded. A total of 559 cases were enrolled in the study. The median follow-up time was 634.5 days (range, 28-1512 days). All patients provided informed consent, and the studies were performed according to the requirements of the institutional review board of Kanagawa Cancer Center.

Pathological review
-------------------

Excised specimens were fixed in a solution of 10% buffered formaldehyde, and the sections were embedded in paraffin. Next, 4-μm-thick sections, including the largest cut surface of the tumor, were prepared and stained using hematoxylin and eosin (HE) as well as alcian blue and elastica-van-Gieson (AB-EVG) to detect cytoplasmic mucin production and the elastic fiber framework. Lymphatic invasion and pulmonary metastasis were evaluated on HE sections. Vascular and pleural invasion was evaluated in AB-EVG sections. Sections were reviewed by 2 observers (M.O. and T.Y.) who were unaware of the clinical data. Tumor size was measured as the maximal diameter on the cut sections of the lung. Pathological stage was determined based on the criteria of the 7^th^TNM classification of Union of International Cancer Control \[[@B11]\].

Histological definition of micropapillary components
----------------------------------------------------

Histopathological diagnosis of lung adenocarcinoma was determined according to the IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma \[[@B1]\]. Comprehensive histological subtyping was performed on the primary tumor and divided by percentage into 5 distinctive subtypes: lepidic, acinar, papillary, micropapillary, and solid, totaling 100% per tumor. We defined the subtype as positive when it occupied at least 1% of the entire tumor. We classified a micropapillary subtype into 2 components, AMPC and SMPC, using the following criteria: AMPC is widely recognized in the lungs as tumor cells floating within alveolar spaces, and SMPC includes papillary components consisting of tufts lacking central fibrovascular cores, surrounded by lacunar spaces and identified as invasive components in the stroma as previously described \[[@B9]\] (Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). Additionally, a tumor area without micropapillary components was defined as a non-micropapillary component (nMPC).

![**Microscopic features of micropapillary component in the lung adenocarcinoma stained with hematoxylin-eosin (HE)**. A, AMPC. AMPC is the micropapillary component in which tumor cells are floating within alveolar spaces. B, SMPC. SMPC are tumor cells observed in the stroma and consisting of a papillary component with a tuft lacking central fibrovascular cores surrounded by lacunar spaces. (A, B: upper panel: magnification, ×100; lower panel: magnification, ×400) SMPC, stromal micropapillary component; AMPC, aerogenous micropapillary component.](1746-1596-7-3-1){#F1}

Tumor tissue microarray (TMA) synthesis
---------------------------------------

TMAs were constructed using a manual tissue-arraying instrument (KIN-4; Azumaya, Tokyo, Japan) as previously described \[[@B12]\], and specimens were punched using a stylet 3 mm in diameter.

Immunohistochemistry
--------------------

The 17 antibodies used for immunohistochemical characterization of tumor cells in TMA in this study are listed in Table [1](#T1){ref-type="table"}. Immunohistochemical staining was performed as follows. TMA recipient blocks were cut into 4-μm-thick sections and mounted on silane-coated slides. HE staining was performed on initial sections to verify histology. The remaining sections were deparaffinized in xylene and dehydrated in a graded alcohol series, and endogenous peroxidase was blocked using 3% hydrogen peroxide in absolute methyl alcohol. Heat-induced epitope retrieval was performed for 20 min at 95°C in 0.02 mol/L citrate buffer (pH 6.0) in samples fixed with 10% formalin if necessary. The slides were rinsed using deionized water and incubated with primary antibodies. They were then washed 3 times in phosphate-buffered saline and incubated with EnVision+ System-HRP (DAKO, Glostrup, Denmark). The reaction products were visualized using 3-3\'-diaminobenzidine tetrahydrochloride, and sections were counterstained using hematoxylin. Additionally, a similar staining method was used for anti-podoplanin antibody (clone D2-40, pre-diluted; Ventana, Tucson, AZ, USA) to evaluate lymphatic permeation.

###### 

Antibodies

  Classification/Antibody           Clone        Dilution      Source
  --------------------------------- ------------ ------------- --------------------------------------
  **Cellular adhesion molecules**                              
   E-cadherin                       NCH-38       1:100         DakoCytomation, Carpinteria, CA, USA
   CD44                             DF1485       1:400         Novocastra, Newcastle upon Tyne, UK
   Laminin5γ2                       4G1          1:50          DakoCytomation, Glostrup, Denmark
  Growth factor                                                
   VEGF-C                           Polyclonal   1:50          Abcam, Cambridge, UK
  Apoptosis-associated proteins                                
   bcl2                             124          1:50          DakoCytomation, Glostrup, Denmark
   p53                              DO-7         Pre-diluted   Nichirei, Tokyo, Japan
   cleaved caspase-3                Polyclonal   1:400         Cell signaling, Danvers, MA, USA
  Mucin-related proteins                                       
   MUC1                             Ma695        1:100         Novocastra, Newcastle upon Tyne, UK
   MUC6                             CLH5         1:100         Novocastra, Newcastle upon Tyne, UK
  Hypoxia induced protein                                      
   HIF-1α                           EP1215Y      1:500         Abcam, Cambridge, UK
  Others                                                       
   TTF-1                            8G7G3/1      1:100         DakoCytomation, Carpinteria, CA, USA
   SP-A                             PE10         1:100         Dako, Kyoto, Japan
   Vimentin                         V9           Pre-diluted   DakoCytomation, Carpinteria, CA, USA
   Ki-67                            MIB-1        1:50          Dako, Glostrup, Denmark
   LYVE1                            15A5B2       1:400         Oriental Yeast, Tokyo, Japan
   c-Met                            EP1454Y      1:200         Abcam, Cambridge, UK
   Phospho-c-Met                    Polyclonal   1:800         Stressgen, Ann Arbor, MI, USA

VEGF-C, vascular endothelial growth factor-C; HIF-1α, hypoxia induced factor 1-α; TTF-1, thyroid transcription factor-1; SP-A, surfactant apoprotein A; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1.

Calculation of staining scores
------------------------------

Immunostaining was scored based on staining intensity and percentage of positively stained cells, with 2 observers evaluating immunostained samples independently. When the observers gave different scores to immunostained samples, the slides were reviewed together under a multiheaded microscope until a consensus was reached. Sections were classified by staining intensity as negative (total absence of staining), 1+ (weak staining), 2+ (moderate staining), or 3+ (strong staining). Staining scores were calculated by multiplying the percentage of positive tumor cells per section (0-100%) by the staining intensity; scores obtained ranged from 0 to 300. Expression of p53, cleaved caspase-3, and Ki-67 were determined by counting 300 tumor cells under a high power field (×400) and results are shown as the percentage of positive cells.

Mutation analysis
-----------------

Mutation analyses of *EGFR*gene exons 19 and 21 and *KRAS*gene codons 12 and 13 were performed using loop-hybrid mobility shift assays and gene sequencing procedures described elsewhere \[[@B13]\].

Statistical analysis
--------------------

All calculations were performed using SPSS software (Dr. SPSS II for Windows Standard version 11.0; SPSS Inc., Chicago, IL, USA). The Chi-square for independence or Fisher\'s exact probability test was performed to analyze differences in patient characteristics between the 2 groups. The Fisher\'s exact probability test was performed if there were 5 or fewer observations in a group. For univariate analysis, all cumulative survival was estimated using the Kaplan-Meier method, and differences in variables were calculated using the log-rank test. Multivariate regression analysis was conducted according to the Cox proportional hazard model. The Mann-Whitney *U*test was used to compare staining scores. Differences were considered significant when the *P*value was less than 0.05.

Results
=======

Clinicopathological characteristics of patients with SMPC
---------------------------------------------------------

Figure [2](#F2){ref-type="fig"} shows a Venn diagram of the relationship between the micropapillary component sets in the 559 patients examined in this study. SMPC was observed in 19 patients (3.4%) and AMPC in 99 (17.7%) patients. A mixture of SMPC and AMPC was observed in 14 patients, pure SMPC without AMPC in 5 patients, and pure AMPC without SMPC in 85 patients. A micropapillary pattern was observed in 50-100% in 2 SMPC tumor and less than 50% in 17 SMPC tumors. No SMPC(+) tumors were completely replaced by SMPC. Clinicopathological characteristics of patients with SMPC(+) and SMPC(-) tumors are summarized in Table [2](#T2){ref-type="table"}. Patients with SMPC(+) tumors were significantly found to be at a more advanced stage, larger than 30 mm in diameter, and have more frequent lymph node metastasis compared to those with SMPC(-) tumors. Pleural, lymphatic, and vascular invasion were observed more often in patients with SMPC(+) tumors than in those with SMPC(-) tumors. (68% vs. 17%, *P*\< 0.001; 74% vs. 15%, *P*\< 0.001; 74% vs. 22%, *P*\< 0.001, respectively). No significant differences in age, gender, or smoking status were observed between patients with SMPC(+) and SMPC(-) tumors.

![**Venn diagram of patients included in the present study**. Among the 559 cases of lung adenocarcinoma, 104 cases had MPC. Nineteen cases had SMPC (SMPC(+) tumors, the area enclosed by continuous line), and 99 had AMPC (AMPC(+) tumors, the area enclosed by dotted line). A mixture of SMPC and AMPC was observed in 14 patients, SMPC without AMPC in 5 and AMPC without SMPC in 85. MPC, micropapillary component; SMPC, stromal micropapillary component; AMPC, aerogenous micropapillary component.](1746-1596-7-3-2){#F2}

###### 

Clinicopathological characteristics of patients with SMPC

                          all     \%   SMPC    *P*value                
  ----------------------- ------- ---- ------- ---------- ------- ---- --------------
  No.                     559          540     97         19      3    
  Age                                                                  
   Median                 67           67                 67           0.219\*
   Range                  23-87        23-87              40-76        
  Gender                                                               
   Female                 288     52   282     52         6       32   0.077\*\*
   Male                   271     48   258     48         13      68   
  Smoking status                                                       
   Nonsmoker              284     51   276     51         8       42   0.596\*\*
   Smoker                 275     49   264     49         11      58   
   BI Average             369          364                502          
  Tumor size                                                           
   Average(mm)            25           25                 35           
   Range(mm)              5-140        5-140              15-75        
   \< 30 mm               396     71   388     72         9       47   \< 0.001\*
   ≥ 30 mm                163     29   152     28         10      53   
  Pathological stage                                                   
   IA                     363     65   360     67         4       21   \< 0.001\*\*
   IB                     95      17   88      16         6       32   
   IIA                    36      6    31      6          5       26   
   IIB                    13      2    13      2          0       0    
   IIIA                   42      8    39      7          3       16   
   ≥ IIIB                 10      2    9       2          1       5    
  Lymph node metastasis                                                
   NX                     69      12   68      13         1       5    
   N0                     420     75   409     75         11      58   0.002\*\*
   ≥ N1                   70      13   63      12         7       21   
  Pleural invasion                                                     
   Negative               452     80   446     83         6       32   \< 0.001\*\*
   Positive               107     20   94      17         13      68   
  Lymphatic invasion                                                   
   Negative               466     83   461     85         5       26   \< 0.001\*\*
   Positive               93      17   79      15         14      74   
  Vascular invasion                                                    
   Negative               427     76   422     78         5       26   \< 0.001\*\*
   Positive               132     24   118     22         14      74   

\* Mann-Whitney\'s U test

\*\* Chi-square for independence test

No., number of patients; BI, Brinkman index = (number of cigarettes per day) × (duration of years); SMPC, stromal micropapillary component; AMPC, aerogeneous micropapillary component

Survival analysis
-----------------

Among all stage patients, median follow-up time was 654 days (range, 33-1512 days) in SMPC(-) tumors, 240 days (range, 28-661 days) in SMPC(+) tumors, 664 days (range, 28-1512 days) in AMPC(-) tumors, and 467 days (range, 36-1412 days) in AMPC(+) tumors. Among the stage I patients, median follow-up time was 767 days (range, 59-1343 days) in SMPC(-) tumors, 192 days (range, 227-485 days) in SMPC(+) tumors, 767 days (range, 59-1343 days) in AMPC(-) tumors, and 836 days (range, 140-1233 days) in AMPC(+) tumors. Recurrence occurred in 28 of 559 cases. SMPC(+) tumors recurred in 4 of 19 in all stage and in 2 of 10 in p-stage I, and AMPC(+) tumors recurred in 8 of 99 cases and 4 of 69 cases, respectively. In all stage, disease-free survival (DFS) of patients with SMPC(+) tumors was significantly poorer than that in patients with SMPC(-) tumors (Figure [3A](#F3){ref-type="fig"}, P \< 0.001); the same result was observed in patients with AMPC(+) and AMPC(-) tumors (Figure [3B](#F3){ref-type="fig"}, P = 0.045,). In p-stage I patients, DFS of those with SMPC(+) tumors showed significantly poorer outcome than that of patients with SMPC(-) tumors (Figure [3C](#F3){ref-type="fig"}, P \< 0.001); the same result was observed between patients with AMPC(+) and AMPC(-) tumors (Figure [3D](#F3){ref-type="fig"}, P = 0.023).

![**Cumulative disease-free survival rates of patients according to presence of SMPC and AMPC**. A, B are cumulative disease-free survival rates in all stage, and C, D are that of in p-stage I. Cumulative disease-free survival rates stratified by presence of SMPC are shown in A and C, and those stratified by presence of AMPC are shown in B and D. In all stage and in p-stage I, SMPC(+) tumors and AMPC(+) tumors had significantly poorer outcomes. Outcomes of SMPC(+) tumors were more significantly negative than those of AMPC(+) tumors. SMPC, stromal micropapillary component; AMPC, aerogenous micropapillary component.](1746-1596-7-3-3){#F3}

In univariate analysis, high pathological stage (*P*\< 0.001), pleural invasion (*P*\< 0.001), lymphatic invasion (*P*\< 0.001), vascular invasion (*P*\< 0.001), SMPC(+) (*P*\< 0.001), and AMPC(+) tumors (*P*= 0.045) showed an unfavorable influence on survival for all stage, and pleural invasion (*P*\< 0.001), lymphatic invasion (*P*\< 0.001), vascular invasion (*P*\< 0.001), SMPC(+) (*P*\< 0.001), and AMPC(+) tumors (*P*= 0.023) showed an unfavorable influence on survival for p-stage I (Table [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). In multivariate analysis, pathological stage (*P*= 0.028), lymphatic invasion (*P*= 0.009), and vascular invasion (*P*= 0.011) were identified as significant independent prognostic factors for all stage (Table [3](#T3){ref-type="table"}). Though not observed for all stage, the presence of SMPC(+) tumors (*P*= 0.035) was identified as a significant independent prognostic factor for p-stage I, as well as lymphatic invasion (*P*= 0.020) and vascular invasion (*P*= 0.049) (Table [4](#T4){ref-type="table"}). The presence of AMPC(+) tumors was not a significant prognostic factor for all stage or p-stage I.

###### 

Impact of potential prognostic factors on DFS of patients of lung adenocarcinoma in all stage by univariate and multivariate analysis

  -----------------------------------------------------------------------------------------------
                       **No**.   \%   Univariate\   Multivariate analysis                 
                                      analysis                                            
  -------------------- --------- ---- ------------- ----------------------- ------------- -------
  Total                559                                                                

  Age                                                                                     

   \< 65               213       38   0.388         1.000                                 

   ≥ 65                346       62                 1.933                   0.849-4.402   0.116

  Gender                                                                                  

   Female              288       52   0.768         1.000                                 

   Male                271       48                 0.807                   0.232-2.803   0.735

  Smoking status                                                                          

   Non-smoker          284       49   0.560         1.000                                 

   Smoker              275       51                 1.164                   0.342-3.956   0.808

  Tumor size                                                                              

   \< 30 mm            396       71   0.059         1.000                                 

   ≥ 30 mm             163       29                 0.819                   0.338-1.985   0.658

  Pathological stage                                                                      

   I                   458       82   \<0.001       1.000                                 

   II, III, IV         101       18                 2.768                   1.113-6.884   0.028

  Pleural invasion                                                                        

   Negative            452       81   \<0.001       1.000                                 

   Positive            107       19                 0.848                   0.345-2.083   0.719

  Lymphatic invasion                                                                      

   Negative            466       83   \<0.001       1.000                                 

   Positive            93        17                 3.430                   1.363-8.634   0.009

  Vascular invasion                                                                       

   Negative            427       76   \<0.001       1.000                                 

   Positive            132       24                 3.309                   1.312-8.350   0.011

  SMPC                                                                                    

   Negative            540       97   \<0.001       1.000                                 

   Positive            19        3                  1.871                   0.528-6.630   0.332

  AMPC                                                                                    

   Negative            460       83   0.045         1.000                                 

   Positive            99        17                 1.132                   0.450-2.845   0.792
  -----------------------------------------------------------------------------------------------

DFS, disease free survival; No., number of patients; SMPC, stromal micropapillary component; AMPC, aerogeneous micropapillary component; CI, confidence interval.

###### 

Impact of potential prognostic factors on DFS of patients of lung adenocarcinoma in p-stage I by univariate and multivariate analysis

  ------------------------------------------------------------------------------------------------
                       **No**.   \%   Univariate\   Multivariate analysis                  
                                      Analysis                                             
  -------------------- --------- ---- ------------- ----------------------- -------------- -------
  Total                458                                                                 

  Age                                                                                      

   \< 65               172       38   0.394         1.000                                  

   ≥ 65                286       62                 2.191                   0.474-10.131   0.316

  Gender                                                                                   

   Female              249       54   0.063         1.000                                  

   Male                209       46                 0.157                   0.014-1.787    0.136

  Smoking status                                                                           

   Non-smoker          248       54   0.204         1.000                                  

   Smoker              210       46                 0.768                   0.117-5.052    0.784

  Tumor size                                                                               

   \< 30 mm            358       78   0.264         1.000                                  

   ≥ 30 mm             100       22                 0.304                   0.037-2.504    0.268

  Pleural invasion                                                                         

   Negative            402       88   \< 0.001      1.000                                  

   Positive            56        12                 1.519                   0.328-7.040    0.593

  Lymphatic invasion                                                                       

   Negative            415       91   \< 0.001      1.000                                  

   Positive            43        9                  5.016                   1.295-19.434   0.020

  Vascular invasion                                                                        

   Negative            390       85   \< 0.001      1.000                                  

   Positive            68        15                 4.494                   1.006-20.081   0.049

  SMPC                                                                                     

   Negative            448       98   \< 0.001      1.000                                  

   Positive            10        2                  9.028                   1.164-70.031   0.035

  AMPC                                                                                     

   Negative            389       98   0.023         1.000                                  

   Positive            69        2                  1.825                   0.378-8.808    0.454
  ------------------------------------------------------------------------------------------------

DFS, disease free survival; No., number of patients; SMPC, stromal micropapillary component; AMPC, aerogeneous micropapillary component; CI, confidence interval.

Immunohistochemical findings
----------------------------

We evaluated immunohistochemical profiles of SMPC, AMPC, and nMPC. These lesions were evaluated in TMAs for 33 cases, including 19 SMPC(+) tumors and 14 pure AMPC tumors. The latter 14 tumors were selected from 85 pure AMPC tumors according to operation date, patient age, gender, and smoking status to match clinical background factors between SMPC and AMPC. nMPC was generally included in TMA cores of SMPC and AMPC. The total number of TMA was 19 SMPC and 28 AMPC. Staining scores are summarized in Table [5](#T5){ref-type="table"}.

###### 

Staining Scores in SMPC, AMPC and nMPC lesions

  Classification/Antibody         SMPC      AMPC       nMPC
  ------------------------------- --------- ---------- -------
  Cellular adhesion molecules                          
   E-cadherin                     215.3\*   143.9      187.1
   CD44                           60.8^‡^   205.9^¶^   141.3
   Laminin5γ2                     69.4      36.9       60.3
  Growth factor                                        
   VEGF-C                         294.4     296.4      282.1
  Apoptosis-associated proteins                        
   bcl2                           13.2      11.1       21.8
   p53^§^                         36.4      26.1       45.0
   cleaved caspase-3^§^           0.3       0.2        0.4
  Mucin-related proteins                               
   MUC1                           169.7     182.5      202.1
   MUC6                           0.0       0.0        0.0
  Hypoxia induced protein                              
   HIF-1α                         1.8       2.4        2.9
  Others                                               
   TTF-1                          267.9     289.3      248.6
   SP-A                           45.2^‡^   82.6       123.2
   Vimentin                       112.1     117.9      72.1
   Ki-67^§^                       22.6      16.9       16.2
   LYVE1                          98.9      107.2      101.9
   c-Met                          217.2     253.8      211.4
   Phospho-c-Met                  34.2^‡^   50.0       88.0

SMPC, stromal micropapillary component; AMPC, aerogeneous micropapillary component; nMPC, non-micropapillary component; VEGF-C, vascular endothelial growth factor-C; HIF-1α, hypoxia induced factor 1-α; TTF-1, thyroid transcription factor-1; SP-A, surfactant apoprotein A; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1.

§ Positivity rate of positive tumor cells in 300 tumor cells (percentage).

\* The difference in staining scores between SMPC and AMPC is statistically significant (*P*= 0.020).

‡ The differences in staining scores between SMPC and nMPC are statistically significant for CD44 (*P*= 0.011), and SP-A (*P*= 0.024) and phospho-c-Met (*P*= 0.011) expression.

¶ The difference in staining scores between AMPC and nMPC is statistically significant (*P*= 0.015).

In cellular adhesion molecules, E-cadherin staining scores in patients with SMPC, AMPC, and nMPC were 215.3, 143.9, and 187.1, respectively, and although the differences were not significant between patients with SMPC or nMPC and between patients with AMPC or nMPC (*P*= 0.312, 0.127, respectively), staining scores of SMPC were significantly higher than those for patients with AMPC (*P*= 0.020) (Figure [4A-C](#F4){ref-type="fig"}). CD44 staining scores in SMPC, AMPC, and nMPC were 60.8, 205.9, and 141.3, respectively. The CD44 expression level in SMPC was significantly lower than in AMPC (*P*\< 0.001) and significantly higher than that in nMPC lesions (*P*= 0.015) (Figure [4D-F](#F4){ref-type="fig"}).

![**Photomicrographs of immunohistochemistry. E-cadherin (A-C); CD44 (D-F); SP-A (G-I); Phospho-c-Met (J-L)**. Compared with AMPC, increased E-cadherin and decreased CD44 membrane immunostaining were found in SMPC. Moreover, SP-A cytoplasm and Phospho-c-Met membrane immunostaining were decreased in SMPC (×400). SMPC, stromal micropapillary component, left panels; AMPC, aerogenous micropapillary component, middle panels; nMPC, non-micropapillary component, right panels.](1746-1596-7-3-4){#F4}

For other antibodies, staining scores of surfactant apoprotein A (SP-A) in the SMPC, AMPC, and nMPC were 45.2, 82.6, and 123.2, respectively, and although the difference was not significant between AMPC and nMPC (*P*= 0.203), the staining score in SMPC was significantly lower than those in nMPC (*P*= 0.024) (Figure [4G-I](#F4){ref-type="fig"}). Similarly, staining scores of phospho-c-Met in SMPC, AMPC, and nMPC were 34.2, 50.5, 88.0, respectively, and staining scores in SMPC were significantly lower than those in nMPC (Figure [4J-L](#F4){ref-type="fig"}).

Mutation analysis
-----------------

Mutation analysis was performed in 33 patients for whom TMAs were constructed for immunohistochemical analysis. Table [6](#T6){ref-type="table"} summarizes the results of the mutation analysis. Although no cases examined possessed the *KRAS*mutations, *EGFR*mutations were detected in 20 cases (61%): 14 in patients with SMPC(+) tumors (74%) and 6 in patients with SMPC(-) tumors (43%). There was no significant association between the existence of SMPC and *EGFR*mutations. Among the 20 cases with *EGFR*mutations, 7 had deletions at exon 19, 13 had a point mutation at exon 21, and there were no multiple mutations. Among the 13 cases with a point mutation at exon 21, 12 had an L858R mutation and one had an L861Q mutation.

###### 

Mutation analysis

                   total   \%      SMPC(+) cases   \%      SMPC(-) cases   \%      *P*value
  ---------------- ------- ------- --------------- ------- --------------- ------- ----------
  No.              33              19                      14                      
  *EGFR*mutation                                                                   
   Negative        13      39      5               26      8               57      0.076\*
   Positive        20      61      14              74      6               43      
   ex19            7       35^§^   5               36^§^   2               33^§^   0.664\*
   ex21            13      65^§^   9               64^§^   4               67^§^   
  *KRAS*mutation                                                                   
   Negative        33      100     19              100     14              100     \-
   Positive        0       0       0                       0                       

No., number of patients; EGFR, epidermal growth factor receptor; SMPC, stromal micropapillary component

\* Fisher\'s exact probability test

§ Rate of positive cases at ex19 and 21 in *EGFR*mutation positive cases, respectively.

Discussion
==========

The present study revealed the incidence of SMPC(+) lung adenocarcinoma in consecutive surgical cases to be 3.4%, which is lower than that of AMPC(+) lung adenocarcinoma (17.7%). In non-pulmonary organs, the incidence of invasive micropapillary carcinoma was reported to be 7% in breast carcinoma \[[@B14]\], 0.9% in urinary bladder cancer \[[@B15]\], and 9.4% in colon cancer \[[@B16]\]. Generally, invasive micropapillary carcinomas occur infrequently in any organ.

Prognosis of lung adenocarcinoma with MPC has been reported to be worse and have the potential for high malignancy \[[@B17],[@B18]\], but no studies have separately evaluated SMPC and AMPC. We showed that SMPC(+) tumors as well as AMPC(+) tumors are associated with several biological factors including tumor size, lymph node metastasis, advanced stage disease, and pleural and lymphovascular invasion. Univariate analysis also revealed the presence of SMPC and AMPC as a significant predictor of unfavorable outcome. However, the most remarkable finding was observed in multivariate analysis: among the patients in p-stage I, patients with not AMPC but SMPC showed a significantly poorer DFS than those without MPC. We used immunohistochemistry with monoclonal antibody D2-40 against lymphatic endothelium in TMA specimens and found that lymphatic vessels are involved within SMPC areas in 4 (21%) of 19 SMPC(+) tumors (data not shown). When compared with AMPC(+) tumors, SMPC(+) tumors significantly more often showed pleural, lymphatic, and vascular invasion than AMPC(+) tumors (68% vs. 33%, *P*= 0.004; 74% vs. 30%, *P*\< 0.001; 74% vs. 41%, *P*= 0.010, respectively). Therefore, these data suggest that a strong association between SMPC(+) tumors and pleural and lymphovascular invasion may in part explain their aggressive behavior.

Moreover, we investigated the immunohistochemical differences between SMPC and AMPC. In the study, we observed high E-cadherin expression and low CD44 expression in SMPC. Phospho-c-Met expression generally decreases in SMPC to a greater extent than in AMPC. Recently, it has been suggested that E-cadherin repression and CD44 expression are associated with the epithelial-mesenchymal transition (EMT), which was thought to lead to tumor invasion \[[@B19],[@B20]\]. Additionally, Elliot et al. reported that hepatocyte growth factor (HGF) and c-Met signaling promotes EMT in breast cancer \[[@B21]\], and Orian-Rousseau et al. reported that CD44 is strictly required for c-Met activation by HGF in human carcinoma \[[@B22]\]. Consistent with these data, EMT may not occur in SMPC despite its existence in the stroma, or invasion of SMPC may occur through a different invasion mechanism from EMT. Our immunohistochemical findings of SMPC showed lower expression of SP-A than that of nMPC. Many studies have reported that SP-A deletion is correlated with patient survival, and reduced SP-A in MPC may be an excellent indicator for poor prognosis in small-size lung adenocarcinoma \[[@B23],[@B24]\]. Reduced SP-A may contribute to an unfavorable outcome of SMPC(+) tumors.

Some studies have reported a significant association between the presence of MPC and *EGFR*mutations and effectiveness of EGFR tyrosine kinase inhibitor (EGFR-TKI) for MPC(+) tumors \[[@B25]-[@B28]\]. Since SMPC of lung adenocarcinoma may be associated with a high incidence of *EGFR*mutations, EGFR-TKI may be effective against SMPC(+) tumors. Patients with these pathological features of lung adenocarcinoma may benefit from EGFR-TKI as postoperative chemotherapy or first-line chemotherapy of relapsed lung adenocarcinoma.

In conclusion, we observed SMPC(+) adenocarcinoma. The incidence of SMPC(+) tumors is low, and SMPC(+) tumors have a different prognostic impact compared to AMPC(+) tumors. Particularly for the early stage tumors, SMPC(+) tumors have different pathobiological characteristics from AMPC(+) tumors, and SMPC(+) tumors frequently contain the *EGFR*mutation. Therefore, it is important to determine the presence of SMPC in lung adenocarcinoma, particularly p-stage I tumors, and the presence of SMPC should be noted in a pathology report to alert the clinician to the possibility of poor prognosis.
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